Roivant reported a Phase 2 success for mosliciguat in interstitial lung disease, with the inhaled therapy meeting key endpoints that could open a path into broader lung-disease programs. In a 16-week study, Roivant said mosliciguat achieved a statistically significant 56% reduction versus placebo in pulmonary vascular resistance, alongside improvements on six-minute walk distance and NT-proBNP. The company positioned the results as surpassing Wall Street’s benchmarks for success. The announcement follows Roivant’s history of licensing and repurposing late-stage assets across respiratory indications, and it adds momentum for investors seeking clinical validation for a non-invasive option targeting pulmonary vascular physiology. For the lung landscape, the readout strengthens the case that targeted inhaled vasomodulation may translate into measurable functional and biomarker changes in patients.